{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:19:41Z","timestamp":1790641181026,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012825","name":"International Visegrad Fund","doi-asserted-by":"publisher","award":["22010090"],"award-info":[{"award-number":["22010090"]}],"id":[{"id":"10.13039\/100012825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LTC19007"],"award-info":[{"award-number":["LTC19007"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LTC19020"],"award-info":[{"award-number":["LTC19020"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA17104"],"award-info":[{"award-number":["CA17104"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["\u00daNKP-21-3"],"award-info":[{"award-number":["\u00daNKP-21-3"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["LINKA20285"],"award-info":[{"award-number":["LINKA20285"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-term treatment of cancer with chemotherapeutics leads to the development of resistant forms that reduce treatment options. The main associated mechanism is the overexpression of transport proteins, particularly P-glycoprotein (P-gp, ABCB1). In this study, we have tested the anticancer and multidrug resistance (MDR) modulation activity of 15 selenocompounds. Out of the tested compounds, <jats:bold>K3<\/jats:bold>, <jats:bold>K4<\/jats:bold>, and <jats:bold>K7<\/jats:bold> achieved the highest sensitization rate in ovarian carcinoma cells (HOC\/ADR) that are resistant to the action of the Adriamycin. These compounds induced oxidation stress, inhibited P-gp transport activity and altered ABC gene expression. To verify the effect of compounds, 3D cell models were used to better mimic in vivo conditions. <jats:bold>K4<\/jats:bold> and <jats:bold>K7<\/jats:bold> triggered the most significant ROS release. All selected selenoesters inhibited P-gp efflux in a dose-dependent manner while simultaneously altering the expression of the ABC genes, especially P-gp in paclitaxel-resistant breast carcinoma cells (MCF-7\/PAX). <jats:bold>K4<\/jats:bold>, and <jats:bold>K7<\/jats:bold> demonstrated sensitization potential in resistant ovarian spheroids. Additionally, all selected selenoesters achieved a high cytotoxic effect in 3D breast and ovarian models, which was comparable to that in 2D cultures. <jats:bold>K7<\/jats:bold> was the only non-competitive P-gp inhibitor, and therefore appears to have considerable potential for the treatment of drug-resistant cancer.<\/jats:p>","DOI":"10.1038\/s41598-022-10311-y","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:03:36Z","timestamp":1650535416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ketone-selenoesters as potential anticancer and multidrug resistance modulation agents in 2D and 3D ovarian and breast cancer in vitro models"],"prefix":"10.1038","volume":"12","author":[{"given":"Simona","family":"Dobiasov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Szemer\u00e9di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Ku\u010derov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Kouck\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"V\u00e1clav\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gbelcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Ruml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Dom\u00ednguez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Viktorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"10311_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"10311_CR2","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski, K., Kciuk, M. & Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"10311_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala, R. J., Gupta, P., Ashby, C. R. Jr. & Chen, Z. S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist. Updat. 18, 1\u201317. https:\/\/doi.org\/10.1016\/j.drup.2014.11.002 (2015).","journal-title":"Drug Resist. Updat."},{"key":"10311_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou, V., Vasiliou, K. & Nebert, D. W. Human ATP-binding cassette (ABC) transporter family. Hum. Genom. 3, 281\u2013290. https:\/\/doi.org\/10.1186\/1479-7364-3-3-281 (2009).","journal-title":"Hum. Genom."},{"key":"10311_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1096\/fj.03-1490fje","volume":"18","author":"ZJ Chen","year":"2004","unstructured":"Chen, Z. J. et al. Association of ABCA2 expression with determinants of Alzheimer\u2019s disease. Faseb J. 18, 1129\u20131131. https:\/\/doi.org\/10.1096\/fj.03-1490fje (2004).","journal-title":"Faseb J."},{"key":"10311_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.bbagen.2018.09.019","volume":"52\u201360","author":"A Domenichini","year":"1863","unstructured":"Domenichini, A., Adamska, A. & Falasca, M. ABC transporters as cancer drivers: Potential functions in cancer development. Biochim. Biophys. Acta Gen. Subj. 52\u201360, 2019. https:\/\/doi.org\/10.1016\/j.bbagen.2018.09.019 (1863).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10311_CR7","first-page":"215","volume":"20","author":"J Kvackajov\u00e1-Kisuck\u00e1","year":"2001","unstructured":"Kvackajov\u00e1-Kisuck\u00e1, J., Baranc\u00edk, M. & Breier, A. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys. 20, 215\u2013237 (2001).","journal-title":"Gen. Physiol. Biophys."},{"key":"10311_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152\u2013162. https:\/\/doi.org\/10.1016\/0005-2736(76)90160-7 (1976).","journal-title":"Biochim. Biophys. Acta"},{"key":"10311_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","volume":"25","author":"MF Fromm","year":"2004","unstructured":"Fromm, M. F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423\u2013429. https:\/\/doi.org\/10.1016\/j.tips.2004.06.002 (2004).","journal-title":"Trends Pharmacol. Sci."},{"key":"10311_CR10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.9b00694","author":"C Chambers","year":"2019","unstructured":"Chambers, C. et al. Defying multidrug resistance! Modulation of related transporters by flavonoids and flavonolignans. J. Agric. Food Chem. https:\/\/doi.org\/10.1021\/acs.jafc.9b00694 (2019).","journal-title":"J. Agric. Food Chem."},{"key":"10311_CR11","doi-asserted-by":"publisher","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","volume":"289","author":"SP Cole","year":"2014","unstructured":"Cole, S. P. Multidrug resistance protein 1 (MRP1, ABCC1), a \u201cmultitasking\u201d ATP-binding cassette (ABC) transporter. J. Biol. Chem. 289, 30880\u201330888. https:\/\/doi.org\/10.1074\/jbc.R114.609248 (2014).","journal-title":"J. Biol. Chem."},{"key":"10311_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/med.21428","volume":"37","author":"D Pe\u00f1a-Sol\u00f3rzano","year":"2017","unstructured":"Pe\u00f1a-Sol\u00f3rzano, D., Stark, S. A., K\u00f6nig, B., Sierra, C. A. & Ochoa-Puentes, C. ABCG2\/BCRP: Specific and nonspecific modulators. Med. Res. Rev. 37, 987\u20131050. https:\/\/doi.org\/10.1002\/med.21428 (2017).","journal-title":"Med. Res. Rev."},{"key":"10311_CR13","doi-asserted-by":"crossref","unstructured":"Gonzalez-Angulo, A. M., Morales-Vasquez, F. & Hortobagyi, G. N. Overview of resistance to systemic therapy in patients with breast cancer. In Breast Cancer Chemosensitivity (eds Dihua Yu & Mien-Chie Hung) 1\u201322 (Springer New York, 2007).","DOI":"10.1007\/978-0-387-74039-3_1"},{"key":"10311_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/bs.acr.2017.07.007","volume":"136","author":"D Bartolini","year":"2017","unstructured":"Bartolini, D. et al. Selenocompounds in cancer therapy: An overview. Adv. Cancer Res. 136, 259\u2013302. https:\/\/doi.org\/10.1016\/bs.acr.2017.07.007 (2017).","journal-title":"Adv. Cancer Res."},{"key":"10311_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.bbrc.2011.04.109","volume":"408","author":"M Freitas","year":"2011","unstructured":"Freitas, M., Alves, V., Sarmento-Ribeiro, A. B. & Mota-Pinto, A. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Biochem. Biophys. Res. Commun. 408, 713\u2013719. https:\/\/doi.org\/10.1016\/j.bbrc.2011.04.109 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10311_CR16","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1016\/j.bmcl.2016.04.064","volume":"26","author":"E Dom\u00ednguez-\u00c1lvarez","year":"2016","unstructured":"Dom\u00ednguez-\u00c1lvarez, E. et al. Identification of selenocompounds with promising properties to reverse cancer multidrug resistance. Bioorg. Med. Chem. Lett. 26, 2821\u20132824. https:\/\/doi.org\/10.1016\/j.bmcl.2016.04.064 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10311_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184563","author":"N Szemeredi","year":"2021","unstructured":"Szemeredi, N. et al. Cyano- and ketone-containing selenoesters as multi-target compounds against resistant cancers. Cancers https:\/\/doi.org\/10.3390\/cancers13184563 (2021).","journal-title":"Cancers"},{"key":"10311_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8080303","author":"J Viktorova","year":"2019","unstructured":"Viktorova, J. et al. Antioxidant, anti-inflammatory, and multidrug resistance modulation activity of silychristin derivatives. Antioxidants. https:\/\/doi.org\/10.3390\/antiox8080303 (2019).","journal-title":"Antioxidants."},{"key":"10311_CR19","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3390\/ijms20122986","volume":"20","author":"P Daniel","year":"2019","unstructured":"Daniel, P., Halada, P., Jel\u00ednek, M., Balu\u0161\u00edkov\u00e1, K. & Kov\u00e1\u0159, J. Differentially expressed mitochondrial proteins in human MCF7 breast cancer cells resistant to paclitaxel. Int. J. Mol. Sci. 20, 2986 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"10311_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.taap.2016.09.020","volume":"310","author":"V N\u011bmcov\u00e1-F\u00fcrstov\u00e1","year":"2016","unstructured":"N\u011bmcov\u00e1-F\u00fcrstov\u00e1, V. et al. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol. Appl. Pharmacol. 310, 215\u2013228. https:\/\/doi.org\/10.1016\/j.taap.2016.09.020 (2016).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10311_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1089\/ars.2007.1528","volume":"9","author":"LV Papp","year":"2007","unstructured":"Papp, L. V., Lu, J., Holmgren, A. & Khanna, K. K. From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid. Redox Signal 9, 775\u2013806. https:\/\/doi.org\/10.1089\/ars.2007.1528 (2007).","journal-title":"Antioxid. Redox Signal"},{"key":"10311_CR22","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.bbagen.2014.10.008","volume":"1642\u20131660","author":"AP Fernandes","year":"1850","unstructured":"Fernandes, A. P. & Gandin, V. Selenium compounds as therapeutic agents in cancer. Biochim. Biophys. Acta 1642\u20131660, 2015. https:\/\/doi.org\/10.1016\/j.bbagen.2014.10.008 (1850).","journal-title":"Biochim. Biophys. Acta"},{"key":"10311_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.bmcl.2017.01.033","volume":"27","author":"M Gajd\u00e1cs","year":"2017","unstructured":"Gajd\u00e1cs, M. et al. Selenoesters and selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer MDR cell line. Bioorg. Med. Chem. Lett. 27, 797\u2013802. https:\/\/doi.org\/10.1016\/j.bmcl.2017.01.033 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10311_CR24","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.21873\/anticanres.13526","volume":"39","author":"A Csonka","year":"2019","unstructured":"Csonka, A. et al. Selenoesters and selenoanhydrides as novel agents against resistant breast cancer. Anticancer Res. 39, 3777\u20133783. https:\/\/doi.org\/10.21873\/anticanres.13526 (2019).","journal-title":"Anticancer Res."},{"key":"10311_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","volume":"15","author":"KM Pluchino","year":"2012","unstructured":"Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R. & Gottesman, M. M. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98\u2013105. https:\/\/doi.org\/10.1016\/j.drup.2012.03.002 (2012).","journal-title":"Drug Resist. Updat."},{"key":"10311_CR26","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1007\/s10637-012-9800-3","volume":"30","author":"PL Kunz","year":"2012","unstructured":"Kunz, P. L. et al. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest. New Drugs 30, 2364\u20132370. https:\/\/doi.org\/10.1007\/s10637-012-9800-3 (2012).","journal-title":"Invest. New Drugs"},{"key":"10311_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1634\/theoncologist.2012-0080","volume":"17","author":"RJ Kelly","year":"2012","unstructured":"Kelly, R. J. et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1\u00ae in combination with paclitaxel in solid tumors. Oncologist 17, 512. https:\/\/doi.org\/10.1634\/theoncologist.2012-0080 (2012).","journal-title":"Oncologist"},{"key":"10311_CR28","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1111\/bph.12889","volume":"171","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. In vitro, in vivo and ex vivo characterization of ibrutinib: A potent inhibitor of the efflux function of the transporter MRP1. Br. J. Pharmacol. 171, 5845\u20135857. https:\/\/doi.org\/10.1111\/bph.12889 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"10311_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lfs.2018.10.048","volume":"214","author":"S Mollazadeh","year":"2018","unstructured":"Mollazadeh, S., Sahebkar, A., Hadizadeh, F., Behravan, J. & Arabzadeh, S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 214, 118\u2013123. https:\/\/doi.org\/10.1016\/j.lfs.2018.10.048 (2018).","journal-title":"Life Sci."},{"key":"10311_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10120483","author":"M Leary","year":"2018","unstructured":"Leary, M., Heerboth, S., Lapinska, K. & Sarkar, S. Sensitization of drug resistant cancer cells: A matter of combination therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10120483 (2018).","journal-title":"Cancers (Basel)."},{"key":"10311_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi, E. & Brunham, L. R. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 12, 339. https:\/\/doi.org\/10.1038\/s41419-021-03614-x (2021).","journal-title":"Cell Death Dis."},{"key":"10311_CR32","doi-asserted-by":"publisher","first-page":"13061","DOI":"10.3390\/molecules190913061","volume":"19","author":"Y Zu","year":"2014","unstructured":"Zu, Y., Yang, Z., Tang, S., Han, Y. & Ma, J. Effects of P-glycoprotein and its inhibitors on apoptosis in K562 cells. Molecules 19, 13061\u201313075 (2014).","journal-title":"Molecules"},{"key":"10311_CR33","doi-asserted-by":"publisher","unstructured":"Dludla, P. et al. The impact of dimethyl sulfoxide on oxidative stress and cytotoxicity in various experimental models. Toxicology. (eds Patel, V. B. & Preedy, V. R.) 243\u2013261 (Academic Press, 2020). https:\/\/doi.org\/10.1016\/B978-0-12-819092-0.00025-X. ISBN 9780128190920.","DOI":"10.1016\/B978-0-12-819092-0.00025-X"},{"key":"10311_CR34","doi-asserted-by":"publisher","first-page":"5381692","DOI":"10.1155\/2019\/5381692","volume":"2019","author":"SJ Kim","year":"2019","unstructured":"Kim, S. J., Kim, H. S. & Seo, Y. R. Understanding of ROS-inducing strategy in anticancer therapy. Oxid. Med. Cell Longev. 2019, 5381692. https:\/\/doi.org\/10.1155\/2019\/5381692 (2019).","journal-title":"Oxid. Med. Cell Longev."},{"key":"10311_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1042\/bj20100368","volume":"429","author":"M Wallenberg","year":"2010","unstructured":"Wallenberg, M., Olm, E., Hebert, C., Bj\u00f6rnstedt, M. & Fernandes, A. P. Selenium compounds are substrates for glutaredoxins: A novel pathway for selenium metabolism and a potential mechanism for selenium-mediated cytotoxicity. Biochem. J. 429, 85\u201393. https:\/\/doi.org\/10.1042\/bj20100368 (2010).","journal-title":"Biochem. J."},{"key":"10311_CR36","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.3390\/nu7053536","volume":"7","author":"S Misra","year":"2015","unstructured":"Misra, S., Boylan, M., Selvam, A., Spallholz, J. E. & Bj\u00f6rnstedt, M. Redox-active selenium compounds\u2014From toxicity and cell death to cancer treatment. Nutrients 7, 3536\u20133556 (2015).","journal-title":"Nutrients"},{"key":"10311_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00204-010-0595-8","volume":"84","author":"J Brozmanov\u00e1","year":"2010","unstructured":"Brozmanov\u00e1, J., M\u00e1nikov\u00e1, D., Vl\u010dkov\u00e1, V. & Chovanec, M. Selenium: a double-edged sword for defense and offence in cancer. Arch Toxicol. 84, 919\u2013938. https:\/\/doi.org\/10.1007\/s00204-010-0595-8 (2010).","journal-title":"Arch Toxicol."},{"key":"10311_CR38","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1021\/jm100576z","volume":"53","author":"M Doering","year":"2010","unstructured":"Doering, M. et al. Synthesis and selective anticancer activity of organochalcogen based redox catalysts. J. Med. Chem. 53, 6954\u20136963. https:\/\/doi.org\/10.1021\/jm100576z (2010).","journal-title":"J. Med. Chem."},{"key":"10311_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jchromb.2016.02.002","volume":"1019","author":"D Bartolini","year":"2016","unstructured":"Bartolini, D. & Galli, F. The functional interactome of GSTP: A regulatory biomolecular network at the interface with the Nrf2 adaption response to oxidative stress. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1019, 29\u201344. https:\/\/doi.org\/10.1016\/j.jchromb.2016.02.002 (2016).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10311_CR40","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/092986712800167392","volume":"19","author":"A Palmeira","year":"2012","unstructured":"Palmeira, A., Sousa, E., Vasconcelos, M. H. & Pinto, M. M. Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Curr. Med. Chem. 19, 1946\u20132025. https:\/\/doi.org\/10.2174\/092986712800167392 (2012).","journal-title":"Curr. Med. Chem."},{"key":"10311_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/molecules24020336","volume":"24","author":"G Spengler","year":"2019","unstructured":"Spengler, G., Gajd\u00e1cs, M., Mar\u0107, M. A., Dom\u00ednguez-\u00c1lvarez, E. & Sanmart\u00edn, C. Organoselenium compounds as novel adjuvants of chemotherapy drugs\u2014A promising approach to fight cancer drug resistance. Molecules 24, 336 (2019).","journal-title":"Molecules"},{"key":"10311_CR42","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.3390\/cancers13184563","volume":"13","author":"N Szemer\u00e9di","year":"2021","unstructured":"Szemer\u00e9di, N. et al. Cyano- and ketone-containing selenoesters as multi-target compounds against resistant cancers. Cancers 13, 4563 (2021).","journal-title":"Cancers"},{"key":"10311_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/cn100078a","volume":"2","author":"P Kannan","year":"2011","unstructured":"Kannan, P. et al. The \u201cSpecific\u201d P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2). ACS Chem. Neurosci. 2, 82\u201389. https:\/\/doi.org\/10.1021\/cn100078a (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"10311_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9050455","author":"S Dobiasova","year":"2020","unstructured":"Dobiasova, S. et al. Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential. Antioxidants. https:\/\/doi.org\/10.3390\/antiox9050455 (2020).","journal-title":"Antioxidants."},{"key":"10311_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111632","volume":"139","author":"M Ganesan","year":"2021","unstructured":"Ganesan, M. et al. Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomed. Pharmacother. 139, 111632. https:\/\/doi.org\/10.1016\/j.biopha.2021.111632 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"10311_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.biopha.2013.10.003","volume":"68","author":"Z Mao","year":"2014","unstructured":"Mao, Z. et al. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K\/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed. Pharmacother. 68, 179\u2013183. https:\/\/doi.org\/10.1016\/j.biopha.2013.10.003 (2014).","journal-title":"Biomed. Pharmacother."},{"key":"10311_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4161\/15384047.2014.987062","volume":"16","author":"T Chen","year":"2015","unstructured":"Chen, T. et al. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol. Ther. 16, 106\u2013114. https:\/\/doi.org\/10.4161\/15384047.2014.987062 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"10311_CR48","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.3390\/ijms16035517","volume":"16","author":"D Antoni","year":"2015","unstructured":"Antoni, D., Burckel, H., Josset, E. & Noel, G. Three-dimensional cell culture: A breakthrough in vivo. Int. J. Mol. Sci. 16, 5517\u20135527 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"10311_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4252\/wjsc.v11.i12.1065","volume":"11","author":"N Chaicharoenaudomrung","year":"2019","unstructured":"Chaicharoenaudomrung, N., Kunhorm, P. & Noisa, P. Three-dimensional cell culture systems as an in vitro platform for cancer and stem cell modeling. World J. Stem Cells 11, 1065\u20131083. https:\/\/doi.org\/10.4252\/wjsc.v11.i12.1065 (2019).","journal-title":"World J. Stem Cells"},{"key":"10311_CR50","doi-asserted-by":"publisher","first-page":"84559","DOI":"10.18632\/oncotarget.19187","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang, J., Seebacher, N., Shi, H., Kan, Q. & Duan, Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8, 84559\u201384571. https:\/\/doi.org\/10.18632\/oncotarget.19187 (2017).","journal-title":"Oncotarget"},{"key":"10311_CR51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1039\/C8MT00369F","volume":"11","author":"MC Ruiz","year":"2019","unstructured":"Ruiz, M. C., Kljun, J., Turel, I., Di Virgilio, A. L. & Le\u00f3n, I. E. Comparative antitumor studies of organoruthenium complexes with 8-hydroxyquinolines on 2D and 3D cell models of bone, lung and breast cancer. Metallomics 11, 666\u2013675. https:\/\/doi.org\/10.1039\/C8MT00369F (2019).","journal-title":"Metallomics"},{"key":"10311_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.Ccr-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho, K., Wang, X., Nie, S., Chen, Z. G. & Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310\u20131316. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1441 (2008).","journal-title":"Clin. Cancer Res."},{"key":"10311_CR53","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3389\/fonc.2019.01541","volume":"9","author":"P Sonkusre","year":"2019","unstructured":"Sonkusre, P. Specificity of biogenic selenium nanoparticles for prostate cancer therapy with reduced risk of toxicity: An in vitro and in vivo study. Front. Oncol. 9, 1541. https:\/\/doi.org\/10.3389\/fonc.2019.01541 (2019).","journal-title":"Front. Oncol."},{"key":"10311_CR54","first-page":"11","volume":"96","author":"DMAJJ Cali","year":"2007","unstructured":"Cali, D. M. A. J. J. Identify P-glycoprotein substrates and inhibitors with the rapid, HTS Pgp-Glo\u2122 assay system. Promega Notes. 96, 11\u201314 (2007).","journal-title":"Promega Notes."},{"key":"10311_CR55","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/foods9050585","volume":"9","author":"J Viktorov\u00e1","year":"2020","unstructured":"Viktorov\u00e1, J. et al. Lemon grass essential oil does not modulate cancer cells multidrug resistance by citral-its dominant and strongly antimicrobial compound. Foods (Basel, Switzerland) 9, 585. https:\/\/doi.org\/10.3390\/foods9050585 (2020).","journal-title":"Foods (Basel, Switzerland)"},{"key":"10311_CR56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S. A. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622. https:\/\/doi.org\/10.1373\/clinchem.2008.112797 (2009).","journal-title":"Clin. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10311-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10311-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10311-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:10:22Z","timestamp":1669342222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10311-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10311"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10311-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6548"}}